Skip to main content
Premium Trial:

Request an Annual Quote

HealthTell Raises $4M to Support Development of Test for Lung, Breast, Prostate, Colorectal Cancer

Premium

Biotech firm HealthTell said this week that it has raised $4 million to support development of its immunosignature diagnostic technology.

The company will put the funds toward validating a test for the early detection of lung, breast, prostate, and colorectal cancers.

“Last year, more than 270,000 Americans died from lung, breast, prostate and colorectal cancers — the top four cancers worldwide,” Bill Colston, co-founder and CEO of HealthTell, said in a statement. “This $4 million in new funding will help HealthTell demonstrate the ability of its test to provide reproducible detection of these tumors at an early stage, when treatment outcomes are significantly improved.”

Founded in 2010 by Colston and Arizona State University Biodesign Institute researchers Stephen Johnston, Neal Woodbury, and John Rajasekaran, HealthTell uses random-sequence peptide microarrays to capture antibodies in patient blood samples. Based on the levels of antibody binding, researchers build antibody expression profiles that can then be correlated with various disease states.

According to HealthTell, the Biodesign researchers have demonstrated the use of the technology in more than 30 illnesses ranging from cancer to infectious disease.

Johnston's lab in 2012 won a $30 million grant from the US Department of Defense's Defense Threat Reduction Agency to build a prototype of a health monitoring chip based on the technology (PM 4/27/2012). HealthTell is supplying chips for this project.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.